Pharmaceutical

AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials

The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.

Jan 5, 2024 - 18:00
AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials
The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.
Read the original article

Tags:

Previous Article

STAT+: Goldman Sachs launches $650 million fund for life sciences investments

Next Article

Signal: UK online pharmacies selling prescription drugs without proper checks

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A replacement for race: Medical experts explore how to eliminate bias in clinical algorithms

A replacement for race: Medical experts explore how to ...

Jun 28, 2023

After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN

After failed FSGS bid, Travere wins full FDA approval f...

Sep 8, 2024

STAT+: Pharmalittle: Telehealth abortion providers are scrambling; Express Scripts launches new pricing plan amid PBM scrutiny

STAT+: Pharmalittle: Telehealth abortion providers are ...

Apr 15, 2023